Disease Landscape and Forecast 인사이트

Clarivate Epidemiology’s coverage of pulmonary hypertension (PH) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed prevalence of PH…

Clarivate Epidemiology’s coverage of pulmonary hypertension (PH) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the diagnosed prevalence of…

Clarivate Epidemiology’s coverage of malignant melanoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…

Clarivate Epidemiology’s coverage of anaplastic lymphoma kinase (ALK) comprises epidemiological estimates of key patient populations with the biomarker in the major mature pharmaceutical markets…

The schizophrenia therapy market is crowded and dominated by atypical and typical antipsychotics. Although the continued generic erosion of oral atypical antipsychotics influences psychiatrists’…

Bipolar disorder (BPD) is a spectrum disorder encompassing two main symptom domains: mania and depression. Atypical antipsychotics, lithium, antiepileptic drugs (AEDs), and antidepressants are the…

Copy/Paste the key inputs from the product brochure, per guidance from Marketing. The urticaria drug market is dominated by oral medications, including steroids and second-generation, nondrowsy…

Bladder cancer is the eighth most diagnosed kind of cancer in China. The bladder cancer therapy market will experience rapid growth over the forecast period, fueled by one of the most robust drug-…

Nonalcoholic steatohepatitis (NASH) is a chronic illness that induces significant and sometimes fatal liver fibrosis; it is one of the primary causes of liver transplantation. In China, where the…

Bladder cancer is the eighth most diagnosed kind of cancer in China. The bladder cancer therapy market will experience rapid growth over the forecast period, fueled by one of the most robust drug-…

The acute lymphoblastic leukemia (ALL) therapy market is growing steadily, fueled by innovations in the treatment paradigm. The availability of premium-priced branded agents prescribed in multidrug…

  The type 2 diabetes (T2D) therapy market is forecast to expand through 2032, supported by polypharmacy and growing use of later-line therapies; however, loss of exclusivity for several…